|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600118689 |
|
最近更新日期: Date of Last Refreshed on: |
2026-02-10 09:09:26 |
|
注册时间: Date of Registration: |
2026-02-10 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
不同利多卡因试验剂量对硬脊膜穿破硬膜外技术下分娩镇痛罗哌卡因起始剂量的影响 |
|
Public title: |
Randomized study of different lidocaine test dose on initial ropivacaine volume for epidural labor analgesia with dural puncture epidural technique |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
不同利多卡因试验剂量对硬脊膜穿破硬膜外技术下分娩镇痛罗哌卡因起始剂量的影响 |
|
Scientific title: |
Randomized study of different lidocaine test dose on initial ropivacaine volume for epidural labor analgesia with dural puncture epidural technique |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
熊祥生 |
研究负责人: |
熊祥生 |
|
Applicant: |
Xiangsheng Xiong |
Study leader: |
Xiangsheng Xiong |
|
申请注册联系人电话: Applicant telephone: |
+86 177 9898 2001 |
研究负责人电话:
Study leader's |
+86 177 9898 2001 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
158193942@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
158193942@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
江苏省淮安市淮阴区淮河东路1号 |
研究负责人通讯地址: |
江苏省淮安市淮阴区淮河东路1号 |
|
Applicant address: |
No. 1, Huaihe East Road, Huaiyin District, Huai'an City, Jiangsu Province |
Study leader's address: |
No. 1, Huaihe East Road, Huaiyin District, Huai'an City, Jiangsu Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
扬州大学附属淮安医院(淮安市第五人民医院) |
||
|
Applicant's institution: |
Huai'an Hospital Affiliated to Yangzhou University (The Fifth People's Hospital of Huai'an) |
||
|
研究负责人所在单位: |
扬州大学附属淮安医院(淮安市第五人民医院) |
||
|
Affiliation of the Leader: |
Huai'an Hospital Affiliated to Yangzhou University (The Fifth People's Hospital of Huai'an) |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
KY-P-2025-44 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
扬州大学附属淮安医院(淮安市第五人民医院)伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of the Huai'an Hospital Affiliated to Yangzhou University (The Fifth People's Hospital of Huai'an) |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-11-03 00:00:00 | ||
|
伦理委员会联系人: |
郭云虎 |
||
|
Contact Name of the ethic committee: |
Yunhu Guo |
||
|
伦理委员会联系地址: |
江苏省淮安市淮阴区淮河东路1号 |
||
|
Contact Address of the ethic committee: |
No. 1, Huaihe East Road, Huaiyin District, Huai'an City, Jiangsu Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 517 8967 0057 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
扬州大学附属淮安医院(淮安市第五人民医院) |
||||||||||||||||||||||
|
Primary sponsor: |
Huai'an Hospital Affiliated to Yangzhou University (The Fifth People's Hospital of Huai'an) |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
江苏省淮安市淮阴区淮河东路1号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 1, Huaihe East Road, Huaiyin District, Huai'an City, Jiangsu Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
淮安市科技计划项目;自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
Science and technology plan project of Huaian; Self-financing |
||||||||||||||||||||||
|
研究疾病: |
分娩期疼痛 |
||||||||||||||||||||||
|
Target disease: |
Pain during laboring |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
探索不同利多卡因试验剂量对硬脊膜穿破硬膜外技术下分娩镇痛罗哌卡因起始剂量的影响。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study aims to determine the 90% effective doses (ED90) of the initial ropivacaine volume with different lidocaine test dose administered under dural puncture epidural (DPE) for epidural labor analgesia. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄18-40岁单胎足月妊娠(包括初产和经产妇)拟椎管内镇痛下行分娩镇痛者;2.宫颈扩张<5cm;VAS评分>5分;3.ASA分级II级 |
||||||||||||||||||||||
|
Inclusion criteria |
1.Patients aged between 18 and 40 years, experiencing a single full - term pregnancy (including primiparas and multiparas), who are scheduled to receive epidural labor analgesia; 2. Cervical dilation less than 5 cm; Visual Analog Scale (VAS) score greater than 5; 3. American Society of Anesthesiologists (ASA) physical status classification grade II. |
||||||||||||||||||||||
|
排除标准: |
1.椎管内镇痛、罗哌卡因或舒芬太尼禁忌者;2.严重的妊娠合并症(心脏病、妊娠期高血压、糖尿病等);3.BMI≥40kg/m2;4.采用其它方式镇痛者; |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Contraindicated for epidural labor analgesia, ropivacaine, or sufentanil; 2. Severe pregnancy - related complications (such as heart disease, gestational hypertension, diabetes, etc.); 3. Body mass index (BMI) equal to or greater than 40 kg/m2; 4. Individuals who utilize other methods for analgesia. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-03-01 00:00:00至 To 2027-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-03-01 00:00:00 至 To 2027-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
计算机生成的随机序列被放入密封的不透明信封中,并按顺序编号 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
A computer-generated randomisation sequence was placed into sealed opaque envelopes and sequentially numbered. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
受试者和研究者双方都不知道受试者被分配到了哪个组别。 |
|
Blinding: |
Both the subjects and the researchers do not know which group the subjects have been assigned to. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
自制指标记录表格 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Self-made record table for indicators |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |